Analytical Studies for Antidoping Purposes

Thesis

Presented for the partial fulfillment of the degree of
PhD in Pharmaceutical Sciences (Pharmaceutical Analytical Chemistry)

By

Naglaa Ibrahim Sayed

Master in Pharmaceutical Sciences (Pharmaceutical Analytical Chemistry)
2012

Under the Supervision of

Prof. Dr.
Laila El-Sayed Abd El-Fattah
Professor of Analytical Chemistry, Faculty of Pharmacy, Cairo university
and Vice Dean for the postgraduate studies affairs and scientific research
Faculty of Pharmacy
Misr University for science and technology

Prof. Dr.
Amira Mabrouk El-Kosasy
Professor of Pharmaceutical Analytical Chemistry and Vice Dean for educational and students affairs
Faculty of Pharmacy
Ain Shams University

Dr.
Omar Abdel-Aziz Ali Ghonim
Associate Professor of Pharmaceutical Analytical Chemistry and Head of the department
Faculty of Pharmacy
Ain Shams University

Faculty of pharmacy
Ain Shams university
2015

Acknowledgment

All thanks and gratitude are to my lord Allah, who has given me the strength and will to finish this work. Words and thanks will never suffice to praise Allah for his mercy, blessings and guidance that lead me through the tough times.

It's my great pleasure to express my sincere thanks and grateful appreciation to ***Prof. Dr. Laila El-Sayed Abd El-Fattah,*** Professor of Analytical Chemistry, Faculty of Pharmacy, Cairo university and Vice Dean for the postgraduate studies affairs and scientific research, Faculty of Pharmacy, Misr University for science and technology, for her valuable suggestions, expert supervision, constructive comments and guidance during the supervision of this work. I will always be indebted to her kindness and continuous encouragement that had made continuation in the hard times attainable.

I would like to express my deepest gratitude and sincere appreciation to ***Prof. Dr. Amira Mabrouk El-Kosasy,*** Professor of Pharmaceutical Analytical Chemistry and Vice Dean for the educational and students affairs, Faculty of Pharmacy, Ain Shams University, for suggesting the point, her kind and expert supervision, patience, unlimited support, generous assistance, and for the extensive effort, time and energy.

My profound thanks are to ***Dr. Omar Abdel-Aziz***, Associate Professor of Pharmaceutical Analytical Chemistry and Head of the department, Faculty of Pharmacy, Ain Shams University, who was always supporting me with constructive advice, persistent encouragement and valuable assistance throughout the whole work.

I am very grateful to my parents, brother, sister and my dear husband for standing by me in every step, their continuous support and encouragement all the way through and giving me all the strength and faith more than I needed.

Finally my sincere appreciation and thanks go to all my colleagues and staff members in Pharmaceutical Analytical Chemistry Department, for their friendly cooperation and constant support.

Naglaa Ibrahim

List of contents

Part I: General Introduction on doping

I.1. History 2

I.2. Doping in sports 2

I.3. World Anti-Doping Agency (WADA) 3

I.4.THE 2015 PROHIBITED LIST WORLD ANTI-DOPING CODE 4

Part II: Literature Review

II.1. General profile of the selected drugs 12

II.2.Pharmacology and use in doping 18

II.2.1. Narcotics 18

II.2.2. Anabolic steroid 18

II.2.3. Corticosteroids 19

II.2.4. Diuretics 20

II.2.5. Stimulants 20

II.2.6. β blocker 20

II.2.7. β agonist 20

II.3. Pharmacokinetics 21

II.3.1. Narcotics 21

II.3.2.Anabolic steroid 22

II.3.3.Corticosteroids 22

II.3.4.Diuretics 22

II.3.5. Stimulants 23

II.3.6. β blocker **23**

II.3.7. β agonist **23**

II.4. Methods of analysis for antidoping purposes **24**

II.4.1. Electochemical methods for antidoping purposes **24**

II.4.2. Capillary electrophoresis **27**

II.4.3. Chromatographic methods for antidoping purposes **33**

II.4.3.1.Gas Chromatography **33**

II.4.3.2.High performance liquid Chromatography **47**

Part III: Electrochemical methods for antidoping purpose

Section A: Comparative study of normal, micro & nano-sized iron oxide particles' electrodes for the determination of Nalbuphine HCl (NLB HCl)

III.A.1. Introduction **90**

III.A.2.Experimental **92**

III.A.2.1.Apparatus **92**

III.A.2.2.Materials **92**

III.A.2.2.1.Reference sample for analyte and interfering drugs **92**

III.A.2.2.2.Reagents **93**

III.A.2.2.3.Standard solutions **94**

III.A.2.3.Procedures **95**

III.A.2.3.1.Fabrication of the membrane **95**

III.A.2.3.2. Preparation and characterization of iron oxide magnetic particles **95**

III.A.2.3.3. Preparation and characterization of iron oxide NPs **96**

III.A.2.3.4. Functionalization of iron oxide ferrofluids 96

III.A.2.3.5.Electrode assembly 97

III.A.2.3.6.Direct potentiometric determination of NLB HCl in its pure sample 98

III.A.2.3.7.Direct potentiometric determination of NLB HCl in spiked plasma samples 98

III.A.2.3.8. Determination of NLB HCl in spiked urine samples 99

III.A.2.3.9.Study of experimental conditions 99

III.A.2.3.9.1.Identification of slope, response time and operative lifetime of the proposed sensors 99

III.A.2.3.9.2. Effect of pH 100

III.A.2.3.9.3. Effect of temperature 100

III.A.2.3.9.4. Effect of foreign compounds 100

III.A.3.Results and Discussion 101

III.A.3.1.Sensor fabrication 101

III.A.3.2. Sensor calibration and response time 104

III.A.3.3. Effect of pH and temperature 104

III.A.3.4.Sensor selectivity 105

III.A.3.5.Potentiometric determination of NLB HCl in plasma and urine 106

III.A.3.6.Figures of Merit 106

Section B: Potentiometric sensor based on molecular imprinted polymer for determination of Tramadol HCl (TMD HCl)

III.B.1. Introduction 120

III.B.2.Experimental 121

III.B.2.1.Apparatus 121

III.B.2.2.Materials 122

III.B.2.2.1.Reference sample 122

III.B.2.2.2.Reagents 122

III.B.2.2.3.Standard solutions 122

III.B.2.3.Procedures 123

III.B.2.3.1. MIP and NIP preparation with bulk polymerization 123

III.B.2.3.2. Preparation of the membrane sensor 124

III.B.2.3.3. Electrode Assembly 124

III.B.2.3.4. Direct potentiometric determination of TMD HCl in its pure sample 125

III.B.2.3.5. Potentiometric determination of TMD HCl in spiked plasma samples 125

III.C.2.3.6. Potentiometric determination of TMD HCl in spiked urine samples 126

III.C.2.3.7. Experimental conditions 126

III.C.2.3.7.1. Identification of slope, response time and operative lifetime of the proposed sensor 126

III.C.2.3.7.2.Effect of pH 127

III.C.2.3.7.3. Effect of temperature 127

III.C.2.3.7.4. Effect of foreign compounds 128

III.B.3. Results and discussion 128

III.B.3.1. Characterization 128

III.B.3.2. Physical characterization of TMD MIP 129

III.B.3.3. Optimal MIP formulation and progenic solvent 129

III.B.3.4. Sensor calibration and response time 131

III.B.3.5. Effect of pH and temperature 131

III.B.3.6. Potentiometric determination of TMD in plasma and urine 132

III.B.3.7. Sensor selectivity 132

III.B.3.8. Figures of Merit 133

Part IV

HPLC / DAD determination of doping drugs

Section A: Introduction to HPLC / DAD and its use for antidoping

IV.A.1. HPLC separation techniques 146

IV.A.2. Reversed phase chromatography 147

IV.A.3. HPLC Detectors 147

IV.A.3.1.Diode array detectors 147

IV.A.4. HPLC/DAD and its use in doping analysis 148

Section B: HPLC / DAD determination of seven doping drugs in pure form with further application to spiked human plasma and urine

IV. B.1. Experimental 151

IV. B.1.1. Apparatus 151

IV.B.1. 2. Materials 151

IV.B.1.2.1. Reference samples 151

IV.B.1.2.2. Reagents 152

IV.B.1.2.3. Standard solutions 152

IV.B.1.2.4. Sample preparation 153

IV.B.1.2.4.1. For plasma **153**

IV.B.1.2.4.2. For urine **153**

IV.B.1.3. Procedure **154**

IV.B.1.3.1. Chromatographic Conditions **154**

IV.B.1.3.2. Method validation **155**

IV.B.1.3.2.1. Linearity **155**

IV.B.1.3.2.2. Accuracy **155**

IV.B.1.3.2.3. Precision **156**

IV.B.1.3.2.3.1. Repeatability (intraday precision) **156**

IV.B.1.3.2.3.2. Intermediate precision (interday precision) **156**

IV.B.1.3.2.4. Selectivity **157**

IV.B.1.3.2.5.. Limit of Detection and Limit of Quantitation **158**

IV.B.2. Results and discussion **158**

IV.B.3. Application to Spiked Human Plasma **162**

IV.B.3. Application to Spiked Human Urine **166**

Part V
HPLC / MS determination of doping drugs
Section A
Introduction to liquid chromatography / mass spectrometry

V.A.1. Theory **208**

V.A.2. Components of Mass spectrometer **209**

V.A.3. Mass spectrometry and doping control **210**

V.A.4. LC/MS and its use for doping analysis **211**

V.A.5. LC/MS versus GC/MS for doping analysis **211**

V.A.6. LC/Tandem mass spectrometry for doping analysis **212**

V.A.6.1. Triple Quadrupole (TQ) mass spectrometer **212**

V.A.6.2.Tandem Mass Spectrometry on the IT **213**

V.A.6.3. The (Quadrupole) Ion-Trap Mass Analyzer 213

Section B

Simultaneous LC / MS/ MS analysis of 14 doping drugs, with further application in human plasma and urine

V.B.1.Experimental 215

V.B.1.1.Instrumentation 215

V.B.1.1.1.Equipment 215

V.B.1.1.2. LC parameters 215

V.B.1.1.3.MS parameters 215

V.B.1.2.Materials 216

V.B.1.2.1.Reference samples 216

V.B.1.2.2.Reagents 217

V.B.1.2.3. Preparation of standard stock and working solutions 217

V.B.1.2.4.Sample preparation 218

V.B.1.2.5.Method Validation 218

V.B.1.2.5.1.Linearity 218

V.B.1.2.5.2.Accuracy 219

V.B.1.2.5.3.Precision 219

V.B.1.2.5.3.1.Repeatability (intraday precision) 219

V.B.1.2.5.3.2.Intermediate precision (interday precision) 220

V.B.1.2.5.5. Limit of Detection and Limit of Quantitation 220

V.B.2. Results and discussion 221

V.B.3. Application to Spiked Human Plasma 225

V.B.3. Application to Spiked Human Urine 229

References 302

List of figures

Figure No.		Page No.
Figure (1):	Determination of synthesized iron oxide MPs' size by Malvern Zetasizer.	97
Figure (2):	Iron oxide NPs under JEOL JEM-2100 Transmission Electron Microscope.	98
Figure (3):	Profile of the potential in mV vs. – log concentration of NLB HCl, using the investigated NLB HCl sensors.	108
Figure (4):	Effect of pH on the response of NLB HCl sensor I.	108
Figure (5):	Effect of pH on the response of NLB HCl sensor II.	109
Figure (6):	Effect of pH on the response of NLB HCl sensor III.	109
Figure (7):	Effect of Temperature on the response of NLB HCl sensor I.	110
Figure (8):	Effect of Temperature on the response of NLB HCl sensor II	110
Figure (9):	Effect of Temperature on the response of NLB HCl sensor III.	111
Figure (10):	Schematic representation of the MIP synthesis.	124
Figure (11):	IR spectra of leached (A) and unleached (B) MIP.	134
Figure (12):	UV absorption spectra of solutions before and after complete washing.	134
Figure (13):	Scanning electron micrographs: (A) leached NIP; (B) unleached MIP; (C) leached MIP.	135
Figure (14):	Profile of the potential in mV vs. – log concentration of TMD HCl, using the investigated MIP and NIP sensors.	136
Figure (15):	Effect of pH on the response of TMD HCl MIP sensor.	136
Figure (16):	Effect of Temperature on the response of TMD HCl MIP sensor.	137

Figure (17): Chromatogram showing simultaneous separation of the seven drugs (10µg ml^{-1}) at λ_{225} nm. 170

Figure (18): Chromatogram showing simultaneous separation of the seven drugs (10µg ml^{-1}) at λ_{272} nm 170

Figure (19): Chromatogram showing simultaneous separation of the seven drugs (10µg ml^{-1}) at λ_{235} nm. 171

Figure (20): Chromatogram showing simultaneous separation of the seven drugs (10µg ml^{-1}) at λ_{242} nm 171

Figure (21): Chromatogram showing simultaneous separation of the seven drugs (10µg ml^{-1}) at λ_{244} nm. 172

Figure (22): Chromatogram showing simultaneous separation of the seven drugs (10µg ml^{-1}) at λ_{239} nm. 172

Figure (23): Linearity of the peak area corresponding to the concentration of HCTZ. 173

Figure (24): Linearity of the peak area corresponding to the concentration of SAL. 173

Figure (25): Linearity of the peak area corresponding to the concentration of FUR. 174

Figure (26): Linearity of the peak area corresponding to the concentration of IDP. 174

Figure (27): Linearity of the peak area corresponding to the concentration of TSE. 175

Figure (28): Linearity of the peak area corresponding to the concentration of SPIRO. 175

Figure (29): Linearity of the peak area corresponding to the concentration of BMS. 176

Figure (30): Chromatogram of blank plasma at λ_{225} nm. 177

Figure (31): Chromatogram of plasma spiked with the seven drugs (each of 2000 ng ml^{-1}) at λ_{225} nm 177

Figure (32): Linearity of the peak area corresponding to the concentration of HCTZ in plasma. 178

Figure (33): Linearity of the peak area corresponding to the concentration of SAL in plasma. 178

Figure (34): Linearity of the peak area corresponding to the concentration of FUR in plasma. 179

Figure (35): Linearity of the peak area corresponding to the concentration of IDP in plasma. 179

Figure (36): Linearity of the peak area corresponding to the concentration of TSE in plasma. 180

Figure (37): Linearity of the peak area corresponding to the concentration of SPIRO in plasma. 180

Figure (38): Linearity of the peak area corresponding to the concentration of BMS in plasma. 181

Figure (39): Chromatogram of blank urine after SPE at λ_{244} nm 182

Figure (40): Chromatogram of urine spiked with the seven drugs at λ_{244} nm after SPE 182

Figure (41): Linearity of the peak area corresponding to the concentration of HCTZ in diluted urine. 183

Figure (42): Linearity of the peak area corresponding to the concentration of SAL in diluted urine. 183

Figure (43): Linearity of the peak area corresponding to the concentration of FUR in urine after SPE. 184

Figure (44): Linearity of the peak area corresponding to the concentration of FUR in diluted urine. 184

Figure (45): Linearity of the peak area corresponding to the concentration of IDP in urine after SPE. 185

Figure (46): Linearity of the peak area corresponding to the concentration of IDP in diluted urine. 185

Figure (47): Linearity of the peak area corresponding to the concentration of TSE in urine after SPE. 186

Figure (48): Linearity of the peak area corresponding to the concentration of TSE in diluted urine. 186

Figure (49): Linearity of the peak area corresponding to the concentration of SPIRO in urine after SPE. 187

Figure (50): Linearity of the peak area corresponding to the concentration of SPIRO in diluted urine. 187

Figure (51): Linearity of the peak area corresponding to the concentration of BMS in urine after SPE. 188

Figure (52): Linearity of the peak area corresponding to the concentration of BMS in diluted urine. 188

Figure (53): Total Ion chromatogram (TIC) showing the drugs determined at both +ve and –ve ESI mode each at 150 ng ml^{-1} 234

Figure (54): Extracted ion chromatogram (XIC) for AMI (a), ATE (b), BMS (c), Caffeine (d), DMS (e),HCTZ (f), IDP (g),

Morphine (h), NLB (I), Pethidine (J), PHE (K), TSE (L), TOR (M) and TMC (N) each at 1000 ng ml^{-1} **235**

Figure (55): MRM for AMI (a), ATE (b), BMS (c), Caffeine (d), DMS (e),HCTZ (f), IDP (g), Morphine (h), NLB (I), Pethidine (J), PHE (K), TSE (L), TOR (M) and TMC (N) each at 1000 ng ml^{-1} **238**

Figure (56): Linearity of the peak area corresponding to the concentration of PHE. **245**

Figure (57): Linearity of the peak area corresponding to the concentration of ATE. **245**

Figure (58): Linearity of the peak area corresponding to the concentration of Morphine. **246**

Figure (59): Linearity of the peak area corresponding to the concentration of AMI. **246**

Figure (60): Linearity of the peak area corresponding to the concentration of NLB. **247**

Figure (61): Linearity of the peak area corresponding to the concentration of Caffeine. **247**

Figure (62): Linearity of the peak area corresponding to the concentration of Pethidine. **248**

Figure (63): Linearity of the peak area corresponding to the concentration of HCTZ. **248**

Figure (64): Linearity of the peak area corresponding to the concentration of TOR. **249**

Figure (65): Linearity of the peak area corresponding to the concentration of DMS. **249**